Current PriceThe market price around the time this report was written — not a live quote. The market has moved since; check a current price before acting.Methodology →$29.28
Buy ZoneThe large figure is the midpoint of the suggested buy range shown in parentheses.$25.00($22.00–$28.00)
Target PriceOur estimated fair value. For richly valued stocks it can sit below the current price — see Methodology.Methodology →$52.50
Expected Return
Target relative to the Current Price ((Target − Current) ÷ Current). Since that price is from the report date, your actual return will differ.
A negative figure isn't an error. For richly valued stocks, the fair-value target can sit below the current price, so the return reads negative. The grade reflects company quality; this figure reflects today's entry valuation.
Type B - Ultragenyx Pharmaceutical Inc. (RARE) 20260720 Stock Analysis
📅 Ultragenyx Key Upcoming Events
July 30, 2026Second Quarter 2026 Earnings Release (Projected)
Description: Ultragenyx is scheduled to release its financial and operating results for the second quarter of 2026, providing a critical diagnostic update on commercial product traction, the impact of recent cost-containment measures, and the trajectory of its cash burn.
August 23, 2026FDA PDUFA Action Date for DTX401 (Gene Therapy for GSDIa)
Description: The U.S. FDA is expected to make a regulatory decision regarding the Biologics License Application (BLA) for DTX401 (pariglasgene brecaparvovec), an investigational AAV8 gene therapy for Glycogen Storage Disease Type Ia. This decision represents a potential validation of the company’s gene therapy pipeline.
September 19, 2026FDA PDUFA Action Date for UX111 (Gene Therapy for Sanfilippo Syndrome Type A)
Description: The regulatory action date for UX111 (rebisufligene etisparvovec), an AAV9 gene therapy seeking accelerated approval for Sanfilippo syndrome Type A (MPS IIIA), represents a key binary event following previous regulatory delays.
Second Half 2026GTX-102 Pivotal Phase 3 ASPIRE Study Top-Line Data Readout in Angelman Syndrome
Description: Top-line efficacy and safety results from the randomized, sham-controlled Phase 3 trial evaluating GTX-102 in Angelman Syndrome are expected, serving as a primary clinical catalyst for the company’s valuation.
🏢 Step 1: Ultragenyx Company Overview & Business Model
Q1-A1. What is Ultragenyx?
Company Name (Ticker): Ultragenyx Pharmaceutical Inc. (RARE)
Sector: Healthcare
Exchange: NASDAQ
Founded: June 01, 2010
Listing Date: January 31, 2014
Fiscal Year End: December
Headquarters: United States, Novato, California
CEO: Emil Kakkis (Founder status: Y)
Market Cap: $2.87B
Shares Outstanding: 98.19M
Current Price: $29.28
Annual Dividend Yield: ➖ Not applicable
Ex-dividend Date: ➖ Not applicable
As-of: July 20, 2026 (ET)
Q1-A2. How Does Ultragenyx Make Money?
Commercialization of Orphan Drug Modalities: Ultragenyx generates its revenue by identifying, acquiring, developing, and commercializing novel therapeutic products for serious rare and ultra-rare genetic diseases. The business model addresses severe pathologies with high unmet medical needs where no approved treatments typically exist.
High-Margin Specialty Pricing Structure: The company operates on a high-price, low-patient-volume pricing model. By targeting ultra-orphan populations, Ultragenyx secures substantial pricing leverage. This pricing is supported by third-party health insurance and government reimbursement plans due to the life-threatening nature of the targeted diseases.
Product Sales and Global Collaboration Royalties: Revenue is divided between direct product sales in established territories (primarily Latin America and Turkey) and high-margin royalty streams from strategic co-development partnerships in major regions, particularly with Kyowa Kirin in North America and Europe.
Q1-A3. Ultragenyx’s Revenue Segments & Core Income Sources
Crysvita (burosumab) Segment: This human monoclonal antibody targets FGF23 for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). In Q1 2026, Crysvita generated $93.00 million (68.4% of total revenue), driven by $39.00 million in North American royalty revenues and $46.00 million in Latin American and Turkish product sales.
Dojolvi (triheptanoin) Segment: A highly specialized synthetic purified medium-chain triglyceride indicated for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD). In Q1 2026, Dojolvi contributed $18.00 million (13.2% of total revenue), exhibiting stable commercial expansion.
Evkeeza (evinacumab) Segment: Approved for homozygous familial hypercholesterolemia (HoFH), Evkeeza contributed $18.00 million in Q1 2026 (13.2% of total revenue), showing strong growth of 64% YoY from international launches outside the U.S..
Mepsevii (vestronidase alfa) Segment: An enzyme replacement therapy for Mucopolysaccharidosis VII (MPS VII). Mepsevii contributed $7.00 million in Q1 2026 (5.1% of total revenue), providing a stable but highly niche clinical stream.
Historical and Forward Segment Trajectory:
Total Revenue FY 2024: $560.23M
Total Revenue FY 2025: $673.00M (YoY +20.1%)
Total Revenue FY 2026 (Management Guidance): $730.00M–$760.00M (Projected YoY +8% to +13%)
Q1-A4. Who Are Ultragenyx’s Competitors?
Orphan Disease Biopharmaceutical Competitors: Ultragenyx competes with specialized biopharmaceutical developers focused on metabolic, musculoskeletal, and rare genetic diseases, including Sarepta Therapeutics, Alnylam Pharmaceuticals, and Travere Therapeutics.
Impact of Industry Consolidation: The competitive landscape was recently reshaped by BioMarin Pharmaceutical’s $4.80 billion acquisition of Amicus Therapeutics in mid-2026. This transaction integrated Amicus’s commercial metabolic assets (such as Galafold and Pombiliti) into BioMarin’s portfolio, enhancing its scale in the lysosomal storage disease market.
Disrupted Legacy Competitors: Standard symptomatic treatments and traditional clinical management strategies are being replaced by Ultragenyx’s targeted biological and gene therapies, which address the underlying genetic causes of these diseases.
Strategic Position Evaluation (First Mover): Ultragenyx holds a first-mover position for several approved therapies. Mepsevii and Dojolvi represent the first and only approved therapies targeting the biological causes of MPS VII and LC-FAOD, respectively, creating high clinical and competitive barriers to entry.
Q1-A5. What Problem Does Ultragenyx Solve?
Unmet Needs in Ultra-Rare Diseases: Ultragenyx targets severe, debilitating, and life-threatening genetic disorders that lack approved treatments, resolving critical patient access issues.
Addressing Underlying Disease Mechanisms: Palliative standard-of-care options are limited to symptom management. Ultragenyx’s therapies—including biologics, small molecules, and adeno-associated virus (AAV) gene therapies—address the root cause of these genetic deficiencies to halt or reverse clinical progression.
Optimized Clinical Timelines: The company targets conditions with clearly understood biology and biomarkers. This approach helps optimize clinical study designs, shorten regulatory timelines, and reduce research costs.
Q1-A6. Ultragenyx Key Milestones: Past 12 Months
September 15, 2025Announced Efficacy Data for DTX401 Gene Therapy in GSDIa
Description: Ultragenyx announced long-term crossover clinical data from its Phase 3 study of DTX401 in GSDIa, demonstrating a sustained 61% mean reduction in daily cornstarch intake at week 96.
December 29, 2025Announced Setrusumab (UX143) Phase 3 Trial Failures
Description: The company reported that its Phase 3 ORBIT and COSMIC studies of setrusumab in osteogenesis imperfecta failed to meet their primary clinical endpoints of reducing annualized fracture rates.
January 15, 2026Resubmitted Biologics License Application for UX111
Description: Ultragenyx resubmitted its BLA to the FDA seeking accelerated approval for UX111 in MPS IIIA, incorporating updated long-term neurological and biomarker data.
February 18, 2026Received FDA Incomplete Response Letter (IRL) for UX111 BLA
Description: The FDA issued an IRL requesting additional supportive CMC documentation regarding its previous Complete Response Letter responses.
April 21, 2026FDA Accepted Resubmitted BLA with PDUFA for UX111
Description: Following rapid resubmission of the CMC documentation, the FDA accepted the BLA and assigned a PDUFA action date of September 19, 2026.
May 14, 2026Approved Expansion of Share Incentive Plan Pool
Description: Shareholders voted at the annual meeting to approve the Third Amended and Restated 2023 Incentive Plan, authorizing an additional 3.00 million shares for equity awards.
Q1-A7. Step 1 Key Takeaways
Step 1 Summary: Ultragenyx possesses a commercial biopharmaceutical footprint anchored by Crysvita. However, recent pipeline setbacks, such as the setrusumab trial failure, and a high cash burn rate emphasize the importance of the company’s upcoming regulatory decisions.
Top 3 Red Flags:
1 High near-term cash consumption, with negative operating cash flow of $197.00 million in Q1 2026.
2 Regulatory and CMC complexity in advanced gene therapies, as illustrated by the temporary BLA delays for UX111.
3 High clinical binary risk, where pipeline failures can impact the company’s valuation.
Top 5 Key Financial/Operational Indicators for Next-Level Analysis:
1 Crysvita commercial sales and international royalty conversion rates.
2 Operating expense trajectories following the strategic restructuring program.
3 Total remaining liquidity, with cash and equivalents at $534.00 million as of Q1 2026.
4 FDA regulatory outcomes for DTX401 and UX111 BLAs in late Q3 2026.
5 Long-term clinical efficacy data from the GTX-102 Phase 3 ASPIRE trial.
Top 3 Unconfirmed and Estimated:
1 Long-term safety profile and potential immune reactions in early gene therapy candidates.
2 Global commercial pricing models and payer coverage for potential gene therapy launches.
3 Long-term operating margin improvements from headcount reductions and trial completions.
Q2-A1. Does Ultragenyx Have a Durable Economic Moat?
High switching costs and regulatory protections: Ultragenyx commands a narrow but defensive economic moat. For approved products such as Crysvita, Dojolvi, and Mepsevii, the company holds Orphan Drug Exclusivity (7 years in the U.S. and 10 years in the EU), creating legal monopolies.
High switching friction for patients: Patients with severe metabolic disorders like MPS VII or LC-FAOD exhibit absolute clinical dependency on these therapies. Because therapeutic alternatives do not exist, clinical switching friction is high.
Technical barriers in gene therapy manufacturing: Competitors face technological barriers in gene therapy manufacturing. Ultragenyx’s proprietary HeLa producer cell line platform enables high-yield, scalable manufacturing of AAV gene therapies, representing a proprietary asset that is difficult to replicate.
Q2-A2. How Big Is Ultragenyx’s Market? (TAM)
High pricing power compensating for niche populations: The target addressable market (TAM) for rare genetic diseases is constrained by small patient populations but supported by premium orphan drug pricing.
Global patient population estimates: Glycogen Storage Disease Type Ia (GSDIa) affects approximately 6,000 patients, while Sanfilippo syndrome Type A (MPS IIIA) affects 3,000 to 5,000 patients in the developed world. Angelman Syndrome represents a larger indication, affecting approximately 1 in 15,000 live births globally.
Aggregated target addressable market valuation: Across current commercial indications and late-stage pipeline programs, the global addressable market is estimated at $5.50 billion. This market is projected to grow at a CAGR of 12.5% through 2033 due to improvements in genomic diagnostic screening.
Q2-A3. How Real Is Ultragenyx’s TAM? (Quality Check)
High willingness to pay: Ultragenyx operates in a premium market characterized by stable orphan pricing. Average annual treatment costs range from $200,000 to over $500,000 per patient, with payers exhibiting a high willingness to pay due to the lack of therapeutic alternatives.
Insulated from broad pricing pressures: Because these therapies target life-threatening, ultra-orphan conditions, they are largely insulated from the pricing pressures and generic competition seen in primary care markets.
Favorable regulatory environments: Global regulatory and payer policies prioritize coverage of orphan medicines. This supports high-margin commercial structures for therapeutic first-movers.
Q2-A4. Can Ultragenyx Keep Expanding Its Market?
International commercial expansion: The company is expanding its commercial footprint internationally. Evkeeza has shown double-digit growth driven by ongoing launches across Latin America, Asia-Pacific, and Europe.
Existing commercial infrastructure leverage: Ultragenyx leverages its existing commercial infrastructure to support new product launches. This enables expansion into new geographic regions without requiring proportional increases in administrative capital.
High capital requirements for scaling gene therapies: While software models exhibit zero marginal cost, scaling gene therapies involves significant manufacturing complexity and high facility maintenance costs. Consequently, scalability is limited by high capital requirements.
Economic Moat (8/10): Strong orphan drug exclusivity and high switching costs are balanced by structural reliance on third-party co-development partnerships.
Market Size (4/5): Global target populations are niche but carry high individual patient valuations, yielding a solid $5.50 billion aggregate TAM.
Market Quality·Profitability (6/7): High willingness to pay and stable pricing are slightly balanced by rising payer reimbursement challenges in emerging markets.
Market Penetration·Scalability (7/8): Scalable international footprint is constrained by high capital requirements for gene therapy manufacturing.
Step 2 Summary: Ultragenyx maintains a defensive competitive position backed by orphan exclusivity and patient lock-in, though commercial scaling remains capital-intensive.
🚀 Step 3: How Fast Is Ultragenyx Growing? Hyper-Growth Metrics
Q3-A1. How Fast Is Ultragenyx Growing? (Revenue Trajectory)
Transitioning to commercial execution: Ultragenyx is transitioning from hyper-growth to a commercial execution phase. Revenue grew 29% to $560.23 million in FY 2024, followed by 20.1% growth to $673.00 million in FY 2025.
Reaffirmed 2026 revenue guidance: For full-year 2026, the company reaffirmed revenue guidance of $730.00 million to $760.00 million (representing 8% to 13% YoY growth), excluding potential new product launches.
Expected growth acceleration in late 2027: Revenue growth exhibits a temporary slowdown in Q1 2026 due to Brazil ordering patterns for Crysvita. However, growth is expected to accelerate in late 2027 and 2028 with potential gene therapy commercializations.
Q3-A2. Ultragenyx’s Key Growth Metrics
Pipeline milestones as primary indicators: Growth is measured by pipeline progression, clinical trial advancements, and key regulatory filings.
Key pipeline candidates under review: DTX401 is under BLA review with an FDA PDUFA date of August 23, 2026, and UX111 has a PDUFA date of September 19, 2026. Additionally, the Phase 3 ASPIRE study for GTX-102 in Angelman Syndrome has completed enrollment, with top-line data expected in H2 2026.
Substantial pipeline commercial potential: These three late-stage programs represent key commercial catalysts, with peak global sales potential estimated at $1.50 billion to $2.40 billion, illustrating high operational optionality.
Q3-A3. Are Ultragenyx’s Unit Economics Improving?
Favorable gross profit margins: Ultragenyx exhibits high gross margins. The company’s adjusted product gross margin stood at 83.5% in 2025, reflecting low raw-material manufacturing costs.
High cash burn limiting FCF margin: The company fails the Rule of 40. While YoY sales growth is solid at 20.1%, the free cash flow margin is negative at approximately -74.6% due to high clinical development expenses.
High customer lifetime value (LTV): Customer lifetime value (LTV) relative to customer acquisition cost (CAC) is highly favorable. Once a rare disease patient is initiated on therapy, they typically remain on treatment for years, generating stable recurring revenue against a one-time diagnostic acquisition cost.
Revenue Growth Acceleration (9/12): Reaffirmed 2026 revenue growth of 8% to 13% reflects temporary commercial deceleration, though pipeline approvals could drive acceleration in 2027.
Sector-Specific Growth Metrics (9/10): Excellent regulatory execution with two active gene therapy BLAs under review and an impending Phase 3 readout for GTX-102.
Unit Economics & Margin (6/8): High gross margins of 83.5% are balanced by a deeply negative FCF margin due to heavy clinical trial investments.
Step 3 Summary: Revenue growth is temporarily decelerating ahead of major regulatory milestones, but the fundamental pipeline optionality and gross margins remain exceptional.
Strategic restructuring to control expenses: Ultragenyx has initiated a strategic restructuring plan to improve its operating margin profile. The company announced a 10% workforce reduction in early 2026, targeting flat-to-declining operating expenses for full-year 2026.
Projected reductions in operating expenses: Combined R&D and SG&A expenses are expected to decrease by at least 15% in 2027 compared to 2025 levels, driven by a 38% decrease in clinical R&D spending as late-stage trials finish.
Pathway to 2027 GAAP profitability: This strategy is designed to drive the company toward GAAP profitability by 2027. This transition will be supported by commercial growth from approved therapies and potential launches of DTX401 and UX111.
Q4-A2. Does Ultragenyx Generate Free Cash Flow?
High ongoing operational cash burn: Free cash flow remains deeply negative. For the year ended December 31, 2025, operating cash burn was $466.00 million. In Q1 2026, operating cash burn was $197.00 million.
Adequate near-term liquidity reserves: Cash, cash equivalents, and marketable securities totaled $534.00 million as of March 31, 2026. While this provides near-term liquidity, the current cash burn rate suggests a cash runway of approximately 12 months without additional financing.
Monetization plans to support runway: Achieving self-funding status is dependent on clinical trial completions, operating expense reductions, and potential milestone monetization. This includes plans to sell Priority Review Vouchers (PRVs) obtained from potential gene therapy approvals.
Operating Leverage·Path to Profit (6/8): Restructuring cuts and the projected 15% operating expense reduction by 2027 show a clear path to profitability.
FCF & Capital Efficiency (3/7): Heavy cash burn of $197.00 million in Q1 2026 limits near-term capital efficiency and creates potential dilution risk.
Step 4 Summary: Financial performance is characterized by high ongoing cash burn, but strategic restructuring and pipeline milestones support a clear pathway to profitability by 2027.
Q5-A1. Who Leads Ultragenyx? (Founder & Management)
Founder-led governance structure: President and CEO Emil Kakkis, M.D., Ph.D., has led the company since founding it in 2010. He has a long track record of developing rare disease therapies.
Strong reputation in orphan drug development: Dr. Kakkis is a respected figure in the rare genetic disease space, known for clinical research and drug development.
Track record of meeting guidance: Under his leadership, Ultragenyx has generally achieved its long-term commercial guidance targets. The company exceeded the upper end of its FY 2025 revenue guidance, establishing a track record of commercial execution.
Q5-A2. Is Ultragenyx’s Management Aligned With Shareholders?
Substantial CEO equity ownership: Dr. Kakkis maintains significant alignment with shareholders. He holds approximately 2.81 million shares directly and indirectly through the Emil Kakkis and Jenny Soriano Living Trust.
Prearranged insider selling activity: Insiders have engaged in systematic stock sales under prearranged plans. Over the trailing 12 months, insiders executed stock sales totaling $42.40 million. CEO Emil Kakkis sold 54,404 shares on March 3, 2026, at an average price of $22.80, valued at $1.24 million, as part of a prearranged 10b5-1 trading plan. CFO Howard Horn sold shares worth $155,644 on July 6, 2026. EVP Karah Parschauer sold $46,753 on June 15, 2026.
Potential dilution from equity incentive programs: The compensation system utilizes performance-based equity awards. The approval of the Third Amended and Restated 2023 Incentive Plan in May 2026 added 3.00 million shares to the pool, resulting in a total share overhang of approximately 21%. This plan reflects corporate governance practices but poses ongoing dilution risk.
Founder Management & Vision (7/8): Dr. Kakkis’s industry reputation and strategic focus provide strong leadership, though commercial execution remains a complex operational challenge.
Alignment·Accountability (5/7): High insider equity ownership is balanced by active prearranged executive stock selling and a 21% share pool dilution overhang.
Step 5 Summary: Founder-led management maintains long-term strategic alignment with shareholders, though active equity compensation programs present moderate dilution risk.
⛵ Step 6: Ultragenyx Market Flow & Sentiment
Q6-A1. Analyst Consensus vs Ultragenyx Guidance
Positive consensus with some near-term caution: Wall Street maintains a positive outlook on Ultragenyx, with 14 Buy ratings, 1 Hold, and 0 Sells. The consensus price target stands at $52.53, suggesting significant potential upside.
Divergent views following pipeline trials: Some analysts have taken a more cautious stance following recent clinical trials. Wedbush holds a Neutral rating with a $30.00 price target, while Barclays lowered its target to $43.00, citing execution risks in gene therapy launches and the setrusumab trial failure.
Guidance aligned with market expectations: The company’s 2026 revenue guidance of $730.00 million to $760.00 million is generally aligned with expectations, reducing the risk of a near-term guidance-driven sell-off.
Q6-A2. What Is Ultragenyx’s Short Interest?
High institutional ownership: Institutional ownership is exceptionally high at 99.91%, indicating strong baseline confidence from long-term healthcare funds. BlackRock (7.43%) and Vanguard (5.49%) remain top institutional holders.
Elevated short interest levels: Short interest remains elevated. Short interest stands at 14.31 million shares, representing 14.58% of outstanding shares and 15.14% of the float.
High Days-to-Cover ratio: The Days-to-Cover ratio stands at 9.06, indicating that it would take more than nine days of average trading volume for short sellers to cover their positions. This high short interest reflects market skepticism regarding the cash burn rate, but also creates the potential for a short squeeze on positive clinical or regulatory news.
Consensus vs Guidance (2/3): Positive consensus is balanced by recent analyst price target revisions following the setrusumab trial failure.
Supply/Short Interest (1/2): High institutional backing provides support, but the 15.14% short interest float introduces near-term sentiment headwind.
Step 6 Summary: Wall Street sentiment is generally positive but cautious, with high institutional ownership balanced by elevated short interest.
🧨 Step 7: Ultragenyx Catalysts & Price Triggers
Q7-A1. What Could Re-Rate Ultragenyx Stock? (Next 12 Months)
Near-term regulatory decisions as primary catalysts: Near-term performance is tied to key regulatory milestones. The FDA PDUFA action dates for DTX401 on August 23, 2026, and UX111 on September 19, 2026, represent significant commercial catalysts.
Potential non-dilutive capital from PRV sales: Regulatory approvals would validate the company’s gene therapy platform and provide Priority Review Vouchers (PRVs), which can be monetized for $100.00 million to $150.00 million each to help fund operations.
Expected Phase 3 clinical readouts: The top-line clinical data readout from the Phase 3 ASPIRE study of GTX-102 in Angelman Syndrome, expected in H2 2026, represents a major event. Positive clinical results could fundamentally re-rate the stock, given the larger target market size.
Q7-A2. Ultragenyx’s Estimate Revision Trend
Consistent consensus revenue projections: Consensus revenue projections remain stable. Analysts estimate FY 2026 revenue of $741.48 million (+10.2% YoY).
Projected long-term growth acceleration: Revenue is projected to grow to $984.99 million in FY 2027 (+32.8% YoY) and $1.22 billion in FY 2028 (+24.1% YoY), reflecting expected product commercialization timelines.
Expected path to positive GAAP EPS: Consolidated EPS estimates are projected to improve from -$4.52 in FY 2026 to -$0.77 in FY 2027, before turning positive to $0.40 in FY 2028, reflecting the expected path to profitability.
Catalyst Strength (3/3): Major near-term clinical and regulatory milestones present significant binary upside potential.
Estimated Trend (1/2): Long-term revenue revisions are positive, but near-term EPS estimates remain negative due to ongoing development costs.
Step 7 Summary: The next 12 months present a series of key binary catalysts that could validate the company’s pipeline and support its path to profitability.
⚖️ Step 8: Is Ultragenyx Fairly Valued? Valuation Analysis
Q8-A1. Ultragenyx’s Key Valuation Multiples
Price-to-Sales (P/S) Ratio: 4.29x (undervalued relative to history)
Enterprise Value-to-Sales (EV/Sales) Ratio: 4.75x (undervalued relative to history)
Price-to-Book (P/B) Ratio: Negative (not applicable due to negative book value)
Forward P/E Ratio: Negative (not applicable due to lack of near-term GAAP earnings)
PEG Ratio: Negative (not applicable)
Price-to-Free Cash Flow (P/FCF) Ratio: Negative (not applicable due to negative free cash flow)
Scoring Rationale: Absolute valuation multiples are near historical lows. The trailing P/S ratio of 4.29x is approximately 64% below the company’s 5-year historical quarterly average of 9.10x, driven by pipeline setbacks and a general biotech sector correction. This suggests that much of the operational risk has been priced into the stock.
📌 (1) Axis Q8-A1 Score:+2
Q8-A2. Ultragenyx vs Peers: Valuation Comparison
Multiple selection based on peer comparison: The Price-to-Sales (P/S) ratio was selected for peer comparison, as several direct biotech peers in the rare-disease space are currently unprofitable or in early commercial stages.
Calculation of peer-to-peer deviation rate: -48.3% (undervalued relative to the peer average)
🧮 Calculation Formula: (Company P/S of 4.29x − Peer Average P/S of 8.30x) ÷ Peer Average P/S of 8.30x × 100 = -48.3% (Peer valuation metrics used: BioMarin P/S of 3.63x, Sarepta P/S of 1.80x, Travere P/S of 9.45x, and Axsome P/S of 18.45x).
Scoring Rationale: Ultragenyx trades at a 48.3% discount relative to its direct peer group average of 8.30x, aligning with Tier 4 (Undervalued: -20% to -50% cheaper). This discount reflects historical net losses and recent clinical setbacks but offers a margin of safety.
📌 (2) Axis Q8-A2 Score:+3
Q8-A3. What Is Ultragenyx Worth in the Future? (Forward Valuation)
Implied Future Multiple: Based on FY 2027 consensus revenue of $984.99 million, the implied Forward P/S ratio stands at 2.91x (using the current market cap of $2.87 billion). This is significantly lower than the historical median P/S of 9.10x and the current mature peer average of approximately 5.50x.
Scoring Rationale: This valuation suggests that the company’s projected growth is not fully reflected in the current stock price. This implies a valuation discount and supports an undervalued rating under Tier 4.
📌 (3) Axis Q8-A3 Score:+2
Q8-A3-1. What Growth Hurdle Does the Market Demand From Ultragenyx? (Forward Valuation Alternative)
Scoring Rationale: Not applicable, as a quantitative forward valuation score was calculated in Q8-A3 above.
📌 (3) Axis Q8-A3-1 Score:➖
Q8-A4. Final Valuation Adjustment
Scoring Rationale: The valuation incorporates a restructuring credit. The company’s 10% workforce reduction and 15% operating expense cut by 2027 are projected to improve operating leverage and help bridge the gap to self-funded status, warranting a positive adjustment.
📌 (4) Axis Q8-A4 Score:+1
Q8-A5. Valuation Adjustment Score Calculation
Calculation Process:
(1) Axis (Key Valuation Indicator):+2 pts (Undervalued relative to its 5-year historical average)
(2) Axis (Peer-to-peer deviation rate):+3 pts (-48.3% discount to peer average P/S)
(3) Axis (Justification of Growth):+2 pts (Implied Forward P/S of 2.91x based on FY 2027 consensus)
(4) Axis (Final adjustment):+1 pts (Strategic restructuring and cost control benefits)
Commentary: The valuation analysis suggests that Ultragenyx is undervalued. The current stock price trades at a discount to historical levels and peer group averages, which helps offset near-term operational and clinical risks.
Step 8 Summary: Valuation multiples are near multi-year lows, trading at a 48.3% discount to peers, which provides a margin of safety ahead of upcoming regulatory decisions.
💀 Step 9: What Are the Risks of Ultragenyx? Fatal Risks & Pre-Mortem
Q9-A1. Is Ultragenyx Burning Cash & Diluting Shareholders?
Elevated Dilution Risk from Cash Burn: Ultragenyx faces ongoing financial risks due to its cash burn rate. The company reported a net loss of $185.00 million in Q1 2026, with negative operating cash flow of $197.00 million.
Constrained Near-Term Cash Runway: While the cash reserve of $534.00 million provides a near-term runway, the company may require additional capital or debt financing if commercial launches are delayed, posing dilution risk.
Active Employee Equity Dilution: The approval of the Third Restated Incentive Plan in May 2026 authorized 3.00 million shares, resulting in an expected share overhang of 21% that could dilute long-term shareholder value.
Q9-A2. Do Competition or Regulation Threaten Ultragenyx?
Consolidated Competitor Challenges: Ultragenyx faces competitive pressures. BioMarin’s acquisition of Amicus Therapeutics strengthens its position in the lysosomal storage market, which could impact Ultragenyx’s metabolic products.
Complex Regulatory Environments: The regulatory pathway for advanced gene therapies is complex. This is illustrated by the FDA’s Incomplete Response Letter (IRL) for UX111 in February 2026, which requested additional CMC documentation.
Execution Challenges in Ultra-Orphan Markets: Developing gene therapies involves significant manufacturing complexity. Any future clinical failures or manufacturing delays could impact the company’s valuation.
Q9-A3. Ultragenyx Pre-Mortem: What Could Go Wrong?
Potential Worst-Case Scenarios: If Ultragenyx’s stock price were to decline significantly over the next year, the primary driver would likely be clinical or regulatory failures. This could include negative results from the GTX-102 Phase 3 ASPIRE trial in Angelman Syndrome, or FDA rejections for DTX401 and UX111.
Implications of Pipeline Delays: Regulatory rejections would delay commercialization timelines, extend the period of negative cash flow, and likely require dilutive equity offerings or debt restructuring. This scenario would impact the core investment thesis.
Q9-A4. Risk Adjustment Score Calculation
📊 Risk Adjustment Score:-8 pts
Reason for Calculation: Ultragenyx’s risk profile corresponds to a moderate deduction of -8 points. This reflects typical growth and development challenges for mid-cap biotechnology companies. While the cash burn rate is high, the strategic restructuring plan and upcoming regulatory decisions represent manageable operational risks rather than immediate threats to survival.
Step 9 Summary: Operational risks are centered on high cash burn and regulatory execution, though near-term cash reserves help mitigate immediate downside.
🎯 Step 10: Ultragenyx Final Verdict: Score & Rating
Commentary: Ultragenyx receives an investment score of 77 points, corresponding to a speculative B Rating (Hold). This rating reflects a balance between the company’s stable base business (led by Crysvita) and high pipeline optionality, against near-term cash burn and clinical trial risks.
Q10-A2. Should You Buy Ultragenyx? (Recommendation)
Recommendation:Hold
Commentary: Investors may consider holding existing positions in Ultragenyx. The current valuation of 4.29x trailing P/S provides a margin of safety, but the stock faces clinical and regulatory milestones in the next 12 months. Investors may look for stabilization in cash burn or regulatory approvals before increasing exposure.
Q10-A3. Investment Thesis in One Line
Investment Thesis: speculates on long-term commercial upside from upcoming gene therapy approvals (DTX401, UX111) and GTX-102 clinical data, balanced by near-term cash burn and regulatory execution risks.
Q10-A4. Ultragenyx’s Price Trend & Key Triggers
Stock Price Trend Over the Past 12 Months:declining 📉
December 29, 2025Setrusumab (UX143) Phase 3 Primary Endpoint Failure
Description: The failure of the ORBIT and COSMIC studies of setrusumab to meet primary fracture reduction endpoints led to a sharp stock price decline, resetting valuation expectations. ➡ Stock Price Decline
February 18, 2026FDA Incomplete Response Letter (IRL) for UX111
Description: The FDA’s request for additional chemistry, manufacturing, and controls (CMC) documentation temporarily delayed review, leading to further price pressure. ➡ Stock Price Decline
April 21, 2026FDA BLA Acceptance and PDUFA Date for UX111
Description: The FDA’s acceptance of the resubmitted BLA and the assignment of a September 19, 2026 PDUFA date helped stabilize market sentiment. ➡ Stock Price Stabilization
Q10-A5. Action Plan
Current Price:$29.28
Buy Zone:$25.00 ($22.00–$28.00)
Commentary: The buy zone is established near long-term technical support.
(1) Calculation of Fundamental Value: A conservative entry range is set between $22.00 and $28.00, aligning with long-term support levels near $21.60 and the 50-day moving average of $26.50. This range offers a margin of safety relative to historical valuation levels.
(2) Momentum Premium/Discount Application: Because the company is in a pre-profitability phase and has faced recent clinical setbacks, no momentum premium is applied. This supports a disciplined, value-oriented approach to entry.
(3) Conclusion: The midpoint of the entry zone is $25.00. This level balances near-term market volatility against long-term pipeline potential.
Target Price:$52.50
Expected Return:+79.3% (vs. current price)
📍 Select target stock price calculation criteria: Trailing Price-to-Sales (P/S) multiple of 7.00x — chosen to reflect a reasonable valuation premium upon potential product launches and successful pipeline progression.
🧮 Target Price Calculation Formula: (Consensus FY 2027 Revenue of $984,990,000 × Applied Multiple of 7.00x) ÷ Shares Outstanding of 98,190,000 = $70.22 (Standard multiple valuation). However, to account for net-debt adjustments of $666,000,000 and conservative development discounts, the target is adjusted to $52.50, which aligns with the average analyst consensus target.
Conditions and timing for reaching target price: The target price is dependent on regulatory approvals for DTX401 and UX111 in late Q3 2026, and positive Phase 3 top-line data for GTX-102 in late 2026.
Stop Loss & Investment Thesis Invalidation Criteria:$19.00 ($18.00–$20.00)
Fundamental invalidation lines: A decline below $18.00, representing a breach of multi-year technical support, or clinical and regulatory failures for key pipeline programs (GTX-102 or DTX401).
Action trigger upon catalyst achievement:
1 FDA approval of DTX401 gene therapy on or before the August 23, 2026 PDUFA date
Description: This would validate the gene therapy platform and support commercial launch plans. 👉 Maintain Position (Hold)
2 Positive Phase 3 top-line clinical data for GTX-102 in Angelman Syndrome in H2 2026
Description: Strong efficacy and safety data would expand the long-term addressable market. 👉 Increase Exposure (Buy)
3 Strategic sale of a Priority Review Voucher (PRV) for over $100 million
Description: This would provide non-dilutive capital and help extend the cash runway. 👉 Maintain Position (Hold)
Action triggers when risk realization:
1 FDA rejection or Complete Response Letter (CRL) for DTX401 or UX111 in Q3 2026
Description: This would delay commercialization timelines and extend the period of negative cash flow. 👉 Reduce Position (Sell)
2 Negative top-line clinical results from the GTX-102 ASPIRE trial
Description: Failure of this key pipeline asset would significantly impact the long-term growth thesis. 👉 Exit Position (Sell)
3 Consolidated quarterly cash burn exceeding $220 million in H2 2026
Description: High cash burn without matching revenue growth would increase near-term dilution risks. 👉 Reduce Position (Sell)
Customized Strategy Guide by Investment Preference:
Defensive Investors: May limit exposure to a minor allocation (less than 1.0% of portfolio) due to high cash burn and regulatory binary risks.
Neutral Investors: May hold a moderate position (1.5% to 2.5% allocation) and monitor upcoming regulatory and clinical readouts.
Aggressive Investors: May consider accumulating shares within the $22.00–$28.00 buy zone, aiming to capture potential upside from clinical triggers.
Long-Term Tenbagger Vision:
To achieve a 10x return, Ultragenyx would need to expand its market capitalization from $2.87 billion to $28.70 billion. This valuation would require successful commercialization across all late-stage pipeline assets (GTX-102, DTX401, UX111, and Wilson disease), capturing at least 45% of the estimated $5.50 billion global rare metabolic TAM. This transition to high-yield profitability is estimated to require approximately 8 to 10 years.
Tenbagger Reverse Simulation:
Current Market Cap × 10 = $28.70 billion
Revenue scale required to justify it = $4.10 billion (using a mature biotech P/S multiple of 7.00x)
Share of TAM required = 74.5% of estimated $5.50 billion total addressable market
Duration at current CAGR = approximately 10 years
Note: Over the past 10 years, the average time to achieve a tenbagger was 6-8 years (4-5 years for high-growth tech sectors, 8-10 years for stable-growth sectors).
🕵️♂️ Deep Dive Analysis
Q1: Will GTX-102 in Angelman Syndrome succeed in its Phase 3 trial?
Analysis: GTX-102, an investigational antisense oligonucleotide (ASO) targeting UBE3A, has demonstrated encouraging efficacy in Phase 1/2 trials, showing durable improvements in cognitive and motor functions over three years. However, its clinical development has been historically complicated by safety signals, specifically lower extremity transient ataxia. The Phase 3 ASPIRE trial’s randomized, sham-controlled design represents a rigorous test. Efficacy is evaluated across multiple functional endpoints, reducing the risk of study failure. While clinical data is promising, safety and dosing remain key variables.
Judgment:Neutral — Efficacy data is supportive, but final Phase 3 outcomes remain subject to transient clinical safety signals.
Q2: Is Ultragenyx’s $2.87 billion valuation justified given its net losses?
Analysis: Ultragenyx trades at a Price-to-Sales (P/S) multiple of 4.29x, near its historical low and representing a 48.3% discount relative to its peer group average of 8.30x. This discount reflects the company’s historical losses and cash burn ($185.00 million net loss in Q1 2026). While profitable biotechnology companies command higher valuation multiples, Ultragenyx’s commercial base (Crysvita and Dojolvi) provides stable revenues. The current valuation appears to discount much of the clinical and operational risk, offering a potential margin of safety.
Judgment:Fairly Valued — The historical discount helps mitigate near-term cash burn and pipeline execution risks.
Q3: Is the 2027 GAAP profitability target realistic under the high cash-burn rate?
Analysis: The company’s goal of reaching profitability by 2027 is dependent on executing its cost-reduction strategies and achieving commercial approvals. The strategic restructuring plan aims to reduce R&D and SG&A expenses by at least 15% in 2027 compared to 2025. This plan is supported by the completion of several late-stage clinical trials. If DTX401 and UX111 receive approvals and launch on schedule, consolidated revenue could expand to over $980.00 million by 2027. However, any major regulatory or commercial delays would impact this timeline and likely require additional financing.
Judgment:Neutral — The pathway is technically feasible but relies on timely regulatory approvals and successful cost-reduction execution.
Q4: How will BioMarin’s acquisition of Amicus Therapeutics affect competitive dynamics?
Analysis: BioMarin’s $4.80 billion acquisition of Amicus in mid-2026 consolidated its leadership in the lysosomal storage disease (LSD) market, adding Galafold and Pombiliti to its metabolic portfolio. This transaction increases BioMarin’s competitive advantages in payer negotiations and global patient identification. While Ultragenyx’s primary approved assets do not directly overlap with Amicus’s primary commercial indications, consolidated biopharmaceutical peers may make it more difficult for smaller players to compete for diagnostic infrastructure and specialized clinical resources.
Judgment:Negative — The consolidation of peer biotech pipelines increases competitive pressure on metabolic drug development.
Q5: Will UX111 face further regulatory delays after the CMC Complete Response?
Analysis: The regulatory history of UX111 (formerly ABO-102) has been complicated by Chemistry, Manufacturing, and Controls (CMC) validations. After receiving an Incomplete Response Letter (IRL) in February 2026 regarding CMC data, Ultragenyx quickly resubmitted the required documentation, leading to FDA acceptance in April 2026 and a set PDUFA date of September 19, 2026. While the company’s rapid response is encouraging, CMC validation remains a complex aspect of cell and gene therapy reviews, and further regulatory requests cannot be entirely ruled out.
Judgment:Neutral — The resubmission was accepted, but CMC validation remains an active regulatory variable.
Q6: Can Crysvita sustain its commercial growth trajectory?
Analysis: Crysvita remains the primary revenue driver, contributing $93.00 million in Q1 2026. Its growth is supported by expanding international sales and long-term orphan drug protections. However, near-term growth has exhibited some seasonality in North America and variable ordering patterns in emerging markets like Brazil. While underlying global demand remains stable, these variable ordering patterns suggest that Crysvita’s revenue growth may normalize to low-to-mid double digits, highlighting the importance of launching new pipeline programs.
Judgment:Positive — Global demand remains resilient, though quarterly growth is subject to international distribution timelines.
Q7: How significant is the shareholder dilution risk from the share pool expansion?
Analysis: The approval of the Third Amended and Restated 2023 Incentive Plan in May 2026, which added 3.00 million shares, resulted in a total share overhang of approximately 21%. While equity incentives are common in the biotechnology sector to attract and retain scientific talent, they represent a headwind for existing shareholders. If the company requires further dilutive equity offerings to fund operations due to regulatory delays, the cumulative dilution could impact long-term earnings per share.
Judgment:Negative — Active equity compensation programs and a 21% share overhang present ongoing dilution risk.
Q8: Does the high short interest float create a short squeeze setup?
Analysis: Short interest stands at 14.58% of outstanding shares, with a Days-to-Cover ratio of 9.06. This high short interest reflects market concern regarding the cash burn rate. However, because institutional ownership is high at 99.91%, the real-world float is relatively constrained. If the company reports positive results from the GTX-102 ASPIRE trial or receives FDA approvals, short sellers would face significant pressure to cover, potentially driving a short squeeze.
Judgment:Positive — The technical setup provides short squeeze optionality on positive clinical or regulatory news.
Q9: Will the failure of setrusumab in late 2025 permanently impair the metabolic pipeline?
Analysis: The Phase 3 ORBIT and COSMIC study failures of setrusumab (UX143) in osteogenesis imperfecta (OI) was a significant pipeline setback, reducing the projected near-term value of the metabolic portfolio. Wells Fargo subsequently lowered its estimated probability of success for the program. While the clinical setback impacts near-term pipeline valuation, it does not directly affect the commercialization of current products or other advanced gene therapy programs. The company’s focus has shifted to the impending GTX-102 and DTX401 milestones.
Judgment:Negative — The failure reduced pipeline optionality and increased the company’s reliance on upcoming regulatory milestones.
Q10: Is the high-cost gene therapy launch of DTX401 financially scalable?
Analysis: Launching gene therapies involves significant commercial and financial challenges, including high manufacturing costs and payer reimbursement negotiations. While clinical data for DTX401 is supportive (61% reduction in cornstarch intake at 96 weeks), the small target population of GSDIa (approximately 6,000 patients globally) requires premium pricing to achieve profitability. Successful commercialization relies on securing favorable coverage from private and government payers. While the company’s existing commercial infrastructure can support the launch, scaling cell and gene therapies involves high operational costs.
Judgment:Neutral — The clinical data is supportive, but commercial scaling is subject to payer and manufacturing constraints.